Therapeutic vaccination for HIV: hopes and challenges : Current Opinion in HIV and AIDS

Secondary Logo

Journal Logo

PROGRESS IN ACHIEVING LONG-TERM HIV REMISSION: Edited by Jean-Daniel Lelièvre and Timothy J. Henrich

Therapeutic vaccination for HIV

hopes and challenges

Stephenson, Kathryn E.a,b,c

Author Information
Current Opinion in HIV and AIDS 13(5):p 408-415, September 2018. | DOI: 10.1097/COH.0000000000000491


Purpose of review 

This review summarizes the recent landscape of HIV therapeutic vaccine research, emphasizing the results of randomized controlled trials that included analytical treatment interruption (ATI) to assess efficacy.

Recent findings 

Therapeutic vaccines for HIV are designed to re-educate the host immune response in HIV-infected individuals to better control viral replication in the absence of antiretroviral therapy. No therapeutic vaccine has yet to induce long-term HIV remission following ATI in a randomized controlled trial. This is likely because the vaccines have not elicited a broad enough immune response to suppress the diverse escape variants that emerge during viral rebound, and have not been used with effective agents to reduce the HIV reservoir. Recent studies in nonhuman primates using combination approaches are showing significant successes, with several candidates eliciting significant antiviral activity following ATI. Future studies pairing these vaccines with effective reservoir reduction hold great promise.


Therapeutic vaccines aim to modulate the immune system of HIV-infected individuals to elicit sustained virologic control in the absence of antiretroviral therapy. Therapeutic vaccines that elicit broad immune responses have recently shown promise in randomized controlled trials and nonhuman primate studies.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid